These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10966009)

  • 1. Coronary artery bypass graft in abciximab-treated patients.
    LeNarz LA
    Ann Thorac Surg; 2000 Aug; 70(2 Suppl):S38-42. PubMed ID: 10966009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.
    Lincoff AM; LeNarz LA; Despotis GJ; Smith PK; Booth JE; Raymond RE; Sapp SK; Cabot CF; Tcheng JE; Califf RM; Effron MB; Topol EJ
    Ann Thorac Surg; 2000 Aug; 70(2):516-26. PubMed ID: 10969673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience in coronary bypass surgery for abciximab-treated patients.
    Lemmer JH
    Ann Thorac Surg; 2000 Aug; 70(2 Suppl):S33-7. PubMed ID: 10966008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
    Tcheng JE
    Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvant therapy with a glycoprotein IIb-IIa inhibitor (abciximab) in coronary angioplasties with a high thrombotic risk].
    Matos V; Marques AM; Oliveira H; Ramos D; Lopes P; Camacho M; Gonsalves A
    Rev Port Cardiol; 1998 Dec; 17(12):1001-5. PubMed ID: 9973861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial.
    Cho L; Marso SP; Bhatt DL; Topol EJ
    J Womens Health Gend Based Med; 2000 Sep; 9(7):741-6. PubMed ID: 11025866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era.
    Adelman AG; Caramori PR; Cohen EA; Chisholm RJ; Côté G; Ducas J; O'Neill BJ; Tcheng JE
    Can J Cardiol; 1998 Aug; 14(8):1057-66. PubMed ID: 9738165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
    Kleiman NS; Lincoff AM; Kereiakes DJ; Miller DP; Aguirre FV; Anderson KM; Weisman HF; Califf RM; Topol EJ
    Circulation; 1998 May; 97(19):1912-20. PubMed ID: 9609084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials.
    van de Werf F
    Eur Heart J; 1996 Mar; 17(3):325-6. PubMed ID: 8737200
    [No Abstract]   [Full Text] [Related]  

  • 11. Current status of cardiac surgery in the abciximab-treated patient.
    Silvestry SC; Smith PK
    Ann Thorac Surg; 2000 Aug; 70(2 Suppl):S12-9. PubMed ID: 10966006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.
    Kereiakes DJ; Lincoff AM; Miller DP; Tcheng JE; Cabot CF; Anderson KM; Weisman HF; Califf RM; Topol EJ
    Circulation; 1998 Mar; 97(9):857-64. PubMed ID: 9521334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
    Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ
    Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
    Mak KH; Challapalli R; Eisenberg MJ; Anderson KM; Califf RM; Topol EJ
    Am J Cardiol; 1997 Oct; 80(8):985-8. PubMed ID: 9352964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial.
    Lincoff AM
    Am Heart J; 2000 Feb; 139(2 Pt 2):S46-52. PubMed ID: 10650316
    [No Abstract]   [Full Text] [Related]  

  • 17. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.
    Roffi M; Mukherjee D; Chew DP; Bhatt DL; Cho L; Robbins MA; Ziada KM; Brennan DM; Ellis SG; Topol EJ
    Circulation; 2002 Dec; 106(24):3063-7. PubMed ID: 12473552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.